Sudden US backing for a global waiver on patent protections for COVID-19 vaccines offers hope to poor nations struggling for doses—but the big pharma industry thinks the notion misguided.
Sudden US backing for a global waiver on patent protections for COVID-19 vaccines offers hope to poor nations struggling for doses—but the big pharma industry thinks the notion misguided.
